通过母体免疫预防婴儿疾病的监管考虑
婴儿免疫规划多在2月龄启动,此前存在免疫空白。母体免疫通过孕期接种、经胎盘转移抗体保护胎儿,但孕妇和儿童临床试验纳入困难,安全性和有效性证据不足,尤其实验性疫苗(如呼吸道合胞病毒疫苗)需随机对照试验并对母婴随访至少1年。本文讨论孕期接种疫苗保护婴儿的临床研究监管考虑,以期为未来疫苗试验提供参考,但不代表机构指南或政策。
要点
- 婴儿免疫规划多从2月龄开始,此前存在免疫空白, younger infants 发病和死亡风险更高。
- 母体免疫主要在孕晚期经胎盘转移保护性抗体给胎儿以降低婴儿感染风险。
- 孕妇和儿童临床试验纳入困难,导致孕期和哺乳期疫苗安全性和有效性证据不足。
核心结论
- 本文讨论评估孕期接种疫苗保护婴儿的临床研究的一般监管考虑,可为未来疫苗试验提供参考,但不提供机构指南或阐述机构政策。
研究设计与样本
- 本文为监管考虑讨论文章,非系统综述或指南,未报告检索范围与样本量。
主要发现
- 儿童免疫规划多在2月龄开始,此前婴儿缺乏足够保护,存在免疫空白。
- 母体免疫通过孕晚期经胎盘转移保护性抗体降低婴儿感染风险。
- 孕妇和儿童临床试验纳入困难,导致孕期和哺乳期疫苗安全性和有效性证据不足。
- 实验性疫苗(如呼吸道合胞病毒疫苗)因安全性、有效性和剂量数据有限而研究更复杂。
- 需随机对照试验并对母亲、胎儿和婴儿进行安全性监测,随访至少1年或更长以评估围产期疫苗暴露相关的长期健康结局。
关键数值与推荐
- 随机对照试验需对母亲、胎儿和婴儿进行安全性监测,随访至少1年或更长。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文不提供机构指南,也不阐述机构政策。
- 孕妇和儿童临床试验纳入困难导致证据不足。
- 实验性疫苗的安全性、有效性和剂量数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Childhood Immunization is one of the critical strategies to decrease infant morbidity and mortality due to infectious diseases, but primary immunization schedules for infants in most countries start at 2 months of age. Childhood vaccines therefore begin providing adequate protection later in life, leaving infants vulnerable to infectious diseases and creating an immunity gap that results in higher morbidity and mortality among younger infants. Maternal immunization, the practice of vaccinating individuals during pregnancy, reduces the risk of infant infection primarily through the transfer of protective maternal antibodies to the fetus during late pregnancy. Although much progress has been made in public health policies to support maternal immunization research, inclusion of pregnant individuals and children in clinical trials remains challenging. This has resulted in paucity of evidence regarding safety and effectiveness of vaccines to support licensure of products intended for use during pregnancy and lactation to prevent disease in the infant. In addition, although safeguards for clinical research in pregnancy are supportive, experimental vaccines, e.g., Respiratory Syncytial Virus, are more complicated to study because data on safety, efficacy, and dosing are limited. This requires randomized controlled trials with safety monitoring for the mother, the fetus, and the infant with follow-up for at least 1 year or longer to assess long-term health outcomes that may be associated with peripartum vaccine exposure. The goal of this paper is to discuss the general regulatory considerations for clinical research to evaluate safety and effectiveness of vaccines administered during pregnancy to protect infants from disease. This could be useful to inform future vaccine trials. This discussion is not intended to provide agency guidance nor to articulate agency policy.
引用
- Mutanga JN, Whitaker BI, Forshee RA, et al. Regulatory considerations for study of infant protection through maternal immunization. Vaccine. 2022. PMID: 35570075. doi:10.1016/j.vaccine.2022.04.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。